期刊文献+

非瓣膜性心房颤动脑卒中危险因素的临床分析 被引量:4

An analysis of the factors leading to the illness of cerebral apoplexy in patients with nonvalvular atrial fibrillation
下载PDF
导出
摘要 目的分析非瓣膜性心房颤动(nonvalvular atrial fibrillation,NVAF)患者发生脑卒中的有关危险因素。方法收集168例NVAF患者临床资料,比较纳入研究的心房颤动患者中合并脑卒中与未合并脑卒中患者的临床特征,分析非瓣膜性心房颤动患者发生脑卒中的危险因素。结果本研究中房颤合并脑卒中的患病率是27.4%。经统计学分析,高龄(年龄>75岁)、糖尿病病史、高血压病史、心力衰竭病史等是非瓣膜性心房颤动患者发生脑卒中的危险因素;多因素Logistic分析显示:年龄、高血压病史、LVEF<50%是发生脑卒中的独立危险因素。结论高龄、高血压病史、左室收缩功能障碍是非瓣膜性心房颤动患者发生脑卒中的独立危险因素。 Objective To recognize the factors that contribute to the illness of cerebral apoplexy in patients with nonvalvular atrial fibrillation (NVAF).Method The clinical data of 168 NVAF patients were collected and compared with the data of those with no cerebral apoplexy.Case -control study was applied to identify the risk factors that contribute to the illness of cerebral apoplexy in patients with NVAF.Findings The morbidity rate of the subjects of our study was 27.38%.The univariate analysis we conducted indicated that senility( 〉75 years), diabetes, hypertension and heart failure were the leading factors resulting in cerebral apoplexy in patients with NVAF.And the multivariable logistic regression analysis indicated that senility, hypertension and left ventricular systolic dysfunction (LVEF 〈50%) were the independent factors that lead to cerebral apoplexy in patients with NVAF.Conclusion senility, hypertension and left ventricular systolic dysfunction were independent risk factors for the illness of cerebral apoplexy in patients with NVAF.
出处 《健康研究》 CAS 2015年第3期287-289,共3页 Health Research
关键词 非瓣膜性心房颤动 脑卒中 危险因素 病例对照研究 nonvalvular atrial fibrillation cerebral apoplexy risk factors case -control study
  • 相关文献

参考文献9

  • 1杜梅花,沈玉祥.非瓣膜性心房颤动血栓栓塞危险性研究现状及进展[J].中华实用诊断与治疗杂志,2010,24(5):421-423. 被引量:4
  • 2Donald M,Thomas JW,Erie PL,et al. Life time risk for development of atrial fibrillation: The framingham heart study [ J ]. Circulation, 2004,110(9) :1042 - 1046.
  • 3孙伟,李广生.非瓣膜性心房颤动脑卒中的危险因素[J].赣南医学院学报,2012,32(4):629-632. 被引量:6
  • 4李小鹰.老年人心房颤动诊治中国专家建议(2011)评介[J].中国实用内科杂志,2012,32(4):257-259. 被引量:37
  • 5Wallentin L, Yusuf S, Ezekowitz MD, et al.. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation : anan- alysis of the RE - LY trial[ J ]. Lancet ,2010,376 (9745) :975 - 983.
  • 6李娜,木胡牙提,卢武红,刘志强,何鹏义.非瓣膜性心房颤动患者脑卒中危险因素的研究[J].中国循环杂志,2012,27(3):189-191. 被引量:14
  • 7The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboem bolism [ J ]. N Eng 1J Med ,2010,363 (26) :2499 - 2510.
  • 8ROCKETAF Study Investigators. Rivaroxaban-once daily,oral,direct factor Xa inhibition compared with vitamin K antagonism for preven- tion of stroke and Embolism Trial in Atrial Fibrillation: rational and design of the ROCKET AF study [ J]. Am Heart J ,2010 ; 159 ( 3 ) : 340. e1 - 347.
  • 9S van Diepen, JA Bakal, FA McAlister, et al. Mortality and read- mission of patients with heart failure, atrial fibrillation, or coronary artery disease undergoing noncardiac surgery: an analysis of 38047 patients[ J]. Circulation ,2011,124 (3) :289 - 296.

二级参考文献81

共引文献56

同被引文献19

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部